Stockreport

Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

Dyne Therapeutics, Inc.  (DYN) 
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm Check Earnings Report
US:NYSE Investor Relations: dynegy.com/investors/presentations-events
PDF - Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjuste [Read more]